글로벌 급성 척수 손상 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

급성 척수 손상 시장 분석

글로벌 급성 척수 손상(ASCI) 시장은 인지도 향상과 치료 옵션의 발전으로 인해 상당한 성장을 경험하고 있습니다. 최근 연구에 자세히 나와 있듯이 척수 손상의 발생률은 도로 교통 사고, 낙상, 스포츠 관련 부상과 같은 요인으로 인해 증가하고 있습니다. 이러한 유병률의 증가는 수술 절차, 재활, 코르티코스테로이드와 같은 약리적 치료를 포함한 효과적인 관리 전략과 혁신적인 치료적 개입을 필요로 합니다. 이 시장은 환자 치료에 중요한 역할을 하는 병원과 외상 센터를 포함한 다양한 의료 환경이 특징입니다. 또한 척추 견인 및 수술적 개입을 위한 첨단 기술의 개발이 시장 확장을 촉진하고 있습니다. 시장의 주요 참여자들은 회복 결과를 개선하는 것을 목표로 하는 새로운 치료법을 도입하기 위해 연구 개발에 집중하고 있습니다. 또한 의료 인프라에 대한 투자 증가와 의료 지출 증가는 ASCI 시장의 성장에 긍정적으로 기여할 것으로 예상됩니다. 전반적으로 발생률 증가, 기술 발전, 강력한 의료 시스템의 조합은 향후 몇 년 동안 글로벌 급성 척수 손상 시장에 대한 유망한 전망을 뒷받침합니다.

급성 척수 손상 시장 규모

글로벌 급성 척수 손상 시장 규모는 2023년에 75억 8천만 달러로 평가되었으며, 2031년까지 115억 5천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 5.40%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

급성 척수 손상 시장 동향

“ 재생 의학 에 대한 집중도 증가 ”

급성 척수 손상(ASCI) 시장은 치료 방법론과 혁신적인 치료 접근 방식의 발전으로 인해 상당한 성장을 목격하고 있습니다. 두드러진 추세 중 하나는 재생 의학, 특히 신경 재생을 촉진하고 ASCI 환자의 기능 회복을 개선하는 것을 목표로 하는 줄기 세포 치료법의 개발에 대한 관심이 높아지는 것입니다. 예를 들어, 중간엽 줄기 세포 (MSC)의 효능을 평가하는 임상 시험은 운동 기능을 회복하고 장애를 줄이는 데 유망한 결과를 보여주고 있습니다. InVivo Therapeutics와 같은 회사는 이러한 추세의 최전선에 있으며 척수 치유를 지원하는 이식형 장치와 생체 재료를 연구하고 있습니다. 또한 신경 보호 약물과 재활 기술의 발전으로 환자 결과가 더욱 향상됩니다. ASCI에 대한 인식이 높아지고 효과적인 치료법에 대한 수요가 증가함에 따라 시장이 확대되어 혁신과 투자의 기회가 제공될 것으로 예상됩니다. 이러한 추세의 통합은 급성 척수 손상 치료 환경의 미래를 형성하는 데 중요할 것입니다.

보고 범위 및 급성 척수 손상 시장 세분화     

Acute Spinal Cord Injury Market Definition

Acute spinal cord injury (ASCI) refers to a sudden and often traumatic damage to the spinal cord that results in a loss of function, including mobility and sensation. This type of injury can occur due to various causes, such as motor vehicle accidents, falls, sports injuries, or violent acts. ASCI can lead to partial or complete loss of motor and sensory function below the level of the injury, classified as complete (total loss of function) or incomplete (some preserved function).

Acute Spinal Cord Injury Market Dynamics

Drivers

• Increasing Incidence of Spinal Cord Injuries

The increasing incidence of spinal cord injuries (SCI) significantly drives the acute spinal cord injury market, as factors such as road traffic accidents, sports injuries, falls, and violence contribute to a rising number of cases. For instance, the National Spinal Cord Injury Statistical Center (NSCISC) reported that approximately 17,730 new spinal cord injury cases occur each year in the United States alone, with vehicle accidents accounting for nearly 38% of these injuries, followed by falls (30%) and acts of violence (14%). Such upward trend underscores the urgent need for effective treatments and interventions, propelling advancements in medical technology, rehabilitation services, and pharmaceutical research. As more individuals are affected by acute spinal cord injuries, the demand for specialized care and innovative solutions in this market continues to grow, highlighting the critical role of addressing this public health concern.

• Rising Particularly in Extreme Sports and Recreational Activities

The increase in sports participation, particularly in extreme sports and recreational activities, is a significant driver of the acute spinal cord injury (ASCI) market, as it correlates with a higher incidence of injuries. According to a study published in the American Journal of Sports Medicine, between 1990 and 2010, the incidence of spinal cord injuries among participants in extreme sports, such as snowboarding, skateboarding, and motocross, increased by over 200%. This surge in injuries highlights the risks associated with high-impact sports and emphasizes the growing need for effective treatment options and rehabilitation services tailored for athletes. As more individuals engage in these activities, the demand for specialized medical care, including surgical interventions, physical therapy, and innovative rehabilitation technologies, will continue to rise, fueling the growth of the ASCI market.

Opportunities

• Increasing Advancements in Medical Technology

Advancements in medical technology have significantly transformed the landscape of acute spinal cord injury (ASCI) treatment, presenting a valuable market opportunity. The development of advanced surgical techniques, particularly minimally invasive procedures, allows for reduced tissue damage, shorter recovery times, and less postoperative pain compared to traditional open surgeries. For instance, robotic-assisted surgeries enable surgeons to perform highly precise operations, enhancing accuracy in decompression and stabilization of the spinal cord while minimizing complications. Techniques like endoscopic discectomy exemplify these advancements, allowing for the removal of herniated discs through small incisions, which leads to quicker patient recovery and rehabilitation. As these technologies continue to evolve, they improve surgical outcomes and increase the efficiency of healthcare delivery, thereby expanding the market for ASCI treatments. This shift toward minimally invasive and robotic-assisted surgeries creates significant potential for growth in the ASCI market, as hospitals and healthcare providers seek to adopt these innovations to enhance patient care and optimize resource utilization. The increasing demand for these advanced solutions underscores the importance of ongoing research and investment in medical technology, solidifying it as a critical market opportunity in the management of acute spinal cord injuries.

• Rising Healthcare Expenditures in Both Emerging and Developed Economies

Rising healthcare expenditures in both emerging and developed economies present a significant market opportunity for the acute spinal cord injury (ASCI) sector. Increased healthcare spending enables governments and private entities to invest in improved healthcare infrastructure, ensuring that hospitals and rehabilitation centers are equipped with state-of-the-art technologies and resources. For instance, in countries such as India and Brazil, escalating healthcare budgets have led to the establishment of specialized spinal injury units and rehabilitation facilities that provide comprehensive care tailored to the needs of patients. This enhanced infrastructure facilitates access to advanced treatment options, such as innovative surgical techniques and cutting-edge rehabilitation therapies, thereby improving patient outcomes and recovery rates. Additionally, higher healthcare expenditures promote research and development, paving the way for new therapeutic approaches and technologies that can further benefit ASCI patients. As healthcare systems evolve and prioritize the treatment of spinal cord injuries, the growing financial investment in health services creates a promising market opportunity for stakeholders, including medical device manufacturers, pharmaceutical companies, and rehabilitation service providers, to expand their offerings and cater to an increasing patient population.

Restraints/Challenges

• Variable regulatory environments across different countries

Variable regulatory environments across different countries pose a significant challenge for the global acute spinal cord injury (ASCI) market, creating barriers to the approval and adoption of new treatments and technologies. Each country has its own regulatory framework governing medical devices and pharmaceuticals, which can lead to inconsistencies in the approval process. For instance, while a novel therapeutic intervention may receive rapid approval in one country, it could face lengthy evaluations and additional trials in another, delaying its availability to patients. Such disparity can stifle innovation and limit the introduction of potentially life-saving technologies. Furthermore, companies may be hesitant to invest in research and development for spinal cord injury treatments if they perceive the regulatory landscape as uncertain or burdensome. Such challenges can hinder access to advanced therapies that could significantly improve patient outcomes. As a result, the variable regulatory environments create significant obstacles for the ASCI market, slowing the pace of innovation and potentially leaving patients without the latest and most effective treatment options.

• Significant Expenses Related to Acute Spinal Cord Injury Treatment

High treatment costs present a significant challenge in the management of acute spinal cord injuries (ASCI), impacting patient access to essential services and hindering market growth. The expenses associated with spinal cord injury treatment can be substantial, encompassing costs for emergency surgery, inpatient rehabilitation, outpatient therapies, and long-term care. For instance, in many countries, the total lifetime cost of care for an individual with a spinal cord injury can be prohibitively high, including ongoing medical expenses and the need for assistive devices. Such financial burdens can deter patients from seeking timely treatment, especially in low- and middle-income countries where healthcare resources are limited, and out-of-pocket expenses may be unaffordable. In regions with inadequate insurance coverage or high copayments, many patients may forego necessary surgeries or rehabilitation services, ultimately leading to poorer health outcomes and increased long-term dependency on healthcare systems. As a result, the high costs associated with spinal cord injury care create barriers for patients and pose a significant challenge for the ASCI market, as healthcare providers strive to deliver effective and affordable treatment options amid rising economic pressures.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Acute Spinal Cord Injury Market Scope

The market is segmented on the basis of type, treatment type, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Complete Spinal Cord Injury
• Incomplete Spinal Cord Injury

Treatment Type

• Corticosteroid
• Surgery
• Spinal Traction

End User

• Hospitals
• Trauma Centers

Acute Spinal Cord Injury Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type, treatment type, and end user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America holds a leading position in the acute spinal cord injury market, driven by heightened awareness of spinal cord injuries and a well-established healthcare infrastructure. The region benefits from cutting-edge medical technologies, advanced treatment options, and ongoing research initiatives aimed at improving patient outcomes. Additionally, strong support from healthcare organizations and increased public awareness campaigns have contributed to early diagnosis and better treatment accessibility. These factors together create a favorable environment for market growth in North America.

Asia-Pacific is anticipated to experience substantial growth in the acute spinal cord injury market during the forecast period, largely driven by the presence of emerging economies like China, India, and Brazil. These countries are witnessing increased investments in healthcare development and infrastructure, which is enhancing the availability of advanced treatments. Additionally, the rising demand for improved healthcare services, coupled with a growing focus on medical research and innovation, is fueling market expansion in this region. This combination of factors positions Asia-Pacific as a key area for future growth in the spinal cord injury market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Acute Spinal Cord Injury Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Acute Spinal Cord Injury Market Leaders Operating in the Market Are:

• Novartis AG (Switzerland)
• Tenax Therapeutics (U.S.)
• Accure Pharma (U.S.)
• Merz Therapeutics (Germany)
• ReNetX Bio, Inc. (U.S.)
• BioArctic AB (Sweden)
• Biotimeinc (U.S.)
• Kringle Pharma, Inc. (U.S.)
• BioAxone (Canada)
• AO Foundation (Switzerland)
• Pfizer Inc. (U.S.)
• PHARMICELL Co., Ltd (South Korea)
• Vertex Pharmaceuticals Incorporated (U.S.)
• Axoltis (Switzerland)
• Biostar Stem Cell Research and Development (Taiwan)

Latest Developments in Acute Spinal Cord Injury Market

• In September 25, 2023, NervGen Pharma Corporation, a clinical-stage biotech company focused on treatments for nervous system damage, announced that the first participant had been dosed in their landmark Phase 1b/2a placebo-controlled clinical trial for NVG-291, their lead compound for spinal cord injury (SCI)
• 2023년 8월, 일본에 본사를 둔 국제 화학 제조업체인 카네카 코퍼레이션(Kaneka Corporation)은 인간 양막 기반 중간엽 줄기 세포에서 유래한 급성 척수 손상 치료제인 KA-301에 대한 1/2상 임상 시험을 시작했습니다. 이 시험을 위한 세포 준비는 NexTEP 프로그램에 따라 일본 과학기술청(JST)의 지원을 받은 기술을 통해 개발되었습니다.
• 2023년 7월, 북아일랜드 벨파스트와 미국 볼티모어에 본사를 둔 NeuroSolv Therapeutics는 글로벌 헬스케어 및 특수 약국 솔루션 회사인 AscellaHealth LLC와 파트너십을 맺었습니다. 이 협력은 NeuroSolv의 임상 시험 개발 프로그램을 확대하고 규제 승인 절차를 신속하게 진행하여 제품인 Perineline의 시장 출시를 앞당기는 것을 목표로 합니다.
• 2022년 6월, Amneal Pharmaceuticals, Inc.는 다발성 경화증 및 기타 척수 장애와 관련된 경직을 치료하도록 설계된 FDA 승인 바클로펜 경구 과립 제품(5, 10 및 20mg 용량으로 제공)인 LYVISPAH의 상업적 출시를 발표했습니다.
• Novartis AG는 2021년 8월 FDA가 2019년 10월에 처음 부과했던 부분적 임상 시험 보류를 해제하여 척추성 근위축증(SMA) 환자를 대상으로 한 OAV-101 척추강내(IT) 임상 시험을 재개할 수 있도록 허용했다고 발표했습니다.
• 글로벌 제약사 미쓰비시타나베파마는 2021년 7월 척수손상 치료제로 개발 중인 MT-3921에 대해 미국 FDA로부터 패스트트랙 지정을 받았다.

SKU-65907